New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies

Autor: William R. Freeman, Kristyn Huffman, Lingyun Cheng, Sang Woong Moon, Yaoyao Sun, Michael J. Sailor, David Warther
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Vascular Endothelial Growth Factor A
intravitreal drug delivery
Proliferative vitreoretinopathy
Pharmaceutical Science
Neurodegenerative
Eye
chemistry.chemical_compound
Macular Degeneration
0302 clinical medicine
Drug Delivery Systems
oct
matrigel
Pharmacology & Pharmacy
Fluorescein Angiography
Tomography
vegf
education.field_of_study
Neovascularization
Pathologic
General Medicine
Diabetic retinopathy
Pharmacology and Pharmaceutical Sciences
VEGF
3. Good health
Vascular endothelial growth factor
Drug Combinations
Choroidal neovascularization
porous silicon
Intravitreal Injections
Proteoglycans
Collagen
Rabbits
medicine.symptom
subretinal injection
Tomography
Optical Coherence
medicine.drug
Research Article
medicine.medical_specialty
Population
dexamethasone
rabbit model of pvr
Intravitreal drug delivery
03 medical and health sciences
Matrigel
Ophthalmology
Proliferative
medicine
Animals
education
Macular edema
Eye Disease and Disorders of Vision
Dexamethasone
Neovascularization
Pathologic
fundus fluorescein angiography
business.industry
Vitreoretinopathy
Proliferative
lcsh:RM1-950
Neurosciences
rabbit model of PVR
medicine.disease
eye diseases
Vitreous Body
030104 developmental biology
lcsh:Therapeutics. Pharmacology
chemistry
OCT
Optical Coherence
Delayed-Action Preparations
030221 ophthalmology & optometry
Laminin
sense organs
business
Vitreoretinopathy
Zdroj: Drug Delivery, Vol 25, Iss 1, Pp 600-610 (2018)
Drug Delivery
Drug delivery, vol 25, iss 1
ISSN: 1521-0464
1071-7544
Popis: Blinding retinal diseases become more epidemic as the population ages. These diseases, such as diabetic retinopathy and macular edema, are of chronic nature and require protracted drug presence at the disease site. A sustained intravitreal porous silicon delivery system with dexamethasone (pSiO2-COO-DEX) was evaluated in a new rabbit model of proliferative vitreoretinopathy (PVR) in a real treatment design. In contrast to the pretreatment design model, pSiO2-COO-DEX was intravitreally injected into the eyes with active inflammation. Subretinal injection of vascular endothelial growth factor (VEGF) and Matrigel induced a late-onset vitreoretinal inflammation that gradually developed into PVR. This method mimics the human disease better than PVR induced by either intravitreal cell injection or trauma. The pSiO2-COO-DEX intervened eyes had minimal PVR, while balanced saline solution or free dexamethasone intervened eyes had significantly more PVR formation. In addition, adding VEGF to the Matrigel for subretinal injection induced greater inflammation and retinal neovascularization in comparison to only Matrigel injected under the medullary ray. Clinical and pathological examinations, including fundus fluorescein angiography and optical coherence tomography, confirmed these changes. In the current study, neither subretinal injection of Matrigel or subretinal injection of VEGF and Matrigel induced choroidal neovascularization. However, the current PVR model demonstrates a chronic course with moderate severity, which may be useful for drug screening studies.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje